Table 1.
Baseline Patient Characteristics
| Characteristics | Patients (N = 299) |
|---|---|
| Age (y) | |
| Median (range) | 68.0 (31–84) |
| Sex, n (%) | |
| Male | 222 (74) |
| Smoking status, n (%) | |
| Current | 116 (39) |
| Former | 134 (45) |
| Never | 49 (16) |
| ECOG PS, n (%) | |
| 0 | 95 (32) |
| 1 | 190 (64) |
| 2 | 11 (4) |
| 3 | 3 (1) |
| Histologic diagnosis, n (%) | |
| Adenocarcinoma | 278 (93) |
| Others | 21 (7) |
| Stage, n (%) | |
| 3 | 11 (4) |
| 4 | 228 (76) |
| Recurrence after surgery | 46 (15) |
| Recurrence after radiotherapy | 14 (5) |
| PD-L1 TPS, n (%) | |
| ≥50% | 65 (21) |
| 1%–49% | 104 (35) |
| <1% | 112 (37) |
| Not investigated | 18 (6) |
| Pre-existing interstitial lung disease, n (%) | 13 (4) |
| Emphysema, n. (%) | 114 (38) |
| Previous thoracic radiotherapy, n (%) | 33 (11) |
ECOG PS, Eastern Cooperative Oncology Group performance status; PD-L1, programmed death-ligand 1; TPS, tumor proportion score.
aSmokers versus never-smokers and greater than or equal to 50% versus less than 50% PD-L1 expression.